Avrina is a highly selective and potent inhibitor of the transcription factor NF-kappaB.

While topical corticosteroids are currently used eczema, eczema, the chronic use because of the due to the potential for significant side effects. Topical calcineurin inhibitors have also shown potential in the treatment of this disease, but these potent immunosuppressive agents have yet to generate long-term security. In preclinical studies was Avrina efficiently to intact skin over several easy-to – manufacture, delivered inexpensive formulations and was effective in reducing associated swelling and inflammation associated with eczema with minimal side effects..

As in presents clinical data from Phase 1/2 Trial Of Avrina drug candidates for dermatitisCorgentech Inc. today announced clinical data from a clinical two Phase 1/2 trials Avrina, Corgentech the NF – kappaB decoy drug candidate for the treatment of atopic dermatitis is a chronic skin disorder that affects as eczema, about 52 million and and children known in the United States, Europe and Japan.‘What is important, ‘Brinker said,’They will also help to develop strategies order to reduce breast cancer incidence and death of this large and growing group both both in the Latin American countries and with to the Hispanic community here in the U.S. ‘.